https://www.live-feeds.com/feed/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfrontContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfronthttps://www.live-feeds.com/feed/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfront#u101180Mon, 05 Oct 2026 03:31:28 +0000Merck entered an exclusive global license agreement with Shanghai-based SciBrunch Therapeutics on September 28, 2026, to develop the preclinical oral KRAS G12D (ON) inhibitor SPR2015. The deal includes an upfront payment of $400 million and total potential payments reaching $2.13 billion through milestones. Merck now holds worldwide rights to manufacture, develop, and commercialize the candidate. The move expands Merck's precision targeted pipeline by focusing on one of the most common mutant forms of KRAS found in human cancers.Why it mattersThe KRAS pathway is a known driver of tumor ce